Disease · MONDO_0100073
Comparisons in its trials22
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 22
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm 2: Decolonization vs Arm 1: Usual Care: deaths from any cause | 0 of 183,013 | 0 of 156,889 | 339,902 | NCT02063867 | Trial comparisons |
| Arm 2: Decolonization vs Arm 1: Usual Care: serious adverse events | 0 of 183,013 | 0 of 156,889 | 339,902 | NCT02063867 | Trial comparisons |
| Telavancin vs Vancomycin: serious adverse events | 38 of 503 | 15 of 509 | 1,012 | NCT00107978 | Trial comparisons |
| Linezolid-without Concomitant Drugs vs Linezolid-with Concomitant Drugs: Factors Considered to Affect the Safety of Linezolid - Concomitant Drugs. | 9 of 97 | 154 of 873 | 970 | NCT00666276 | Trial comparisons |
| Linezolid Without Renal Dysfunctions vs Linezolid- With Renal Dysfunctions: Factors Considered to Affect the Safety of Linezolid - Renal Dysfunctions. | 125 of 765 | 38 of 205 | 970 | NCT00666276 | Trial comparisons |
| Linezolid-without Hepatic Dysfunctions vs Linezolid- With Hepatic Dysfunctions: Factors Considered to Affect the Safety of Linezolid - Hepatic Dysfunctions. | 137 of 856 | 26 of 114 | 970 | NCT00666276 | Trial comparisons |
| Linezolid-administrated Over 15 Days vs Linezolid-administrated Less Than 15 Days: Factors Considered to Affect the Safety of Linezolid - Duration of Drug Administration. | 53 of 203 | 110 of 767 | 970 | NCT00666276 | Trial comparisons |
| Linezolid-without Non-drug Therapies vs Linezolid-with Non-drug Therapies: Factors Considered to Affect the Safety of Linezolid - Non-drug Therapies. | 87 of 610 | 76 of 360 | 970 | NCT00666276 | Trial comparisons |
| Linezolid-male vs Linezolid-female: Factors Considered to Affect the Safety of Linezolid - Gender. | 109 of 662 | 54 of 308 | 970 | NCT00666276 | Trial comparisons |
| Linezolid-over 65 vs Linezolid-less Than 65: Factors Considered to Affect the Safety of Linezolid - Age | 122 of 688 | 41 of 282 | 970 | NCT00666276 | Trial comparisons |
| Telavancin vs Vancomycin: serious adverse events | 31 of 426 | 27 of 429 | 855 | NCT00091819 | Trial comparisons |
| Linezolid -Over 40kg vs Linezolid -Less Than 40kg: Factors Considered to Affect the Safety of Linezolid - Weight. | 108 of 651 | 20 of 96 | 747 | NCT00666276 | Trial comparisons |
| Study Drug 1 vs Study Drug 2: serious adverse events | 0 of 49 | 2 of 50 | 99 | NCT01162733 | Trial comparisons |
| Treatment vs Observation: Pulmonary Exacerbations | 2 of 24 | 6 of 21 | 45 | NCT01349192 | Trial comparisons |
| Treatment vs Observation: Antibiotic Use (Proportion of Subjects) | 17 of 24 | 13 of 21 | 45 | NCT01349192 | Trial comparisons |
| Treatment vs Observation: serious adverse events | 1 of 24 | 1 of 21 | 45 | NCT01349192 | Trial comparisons |
| Treatment vs Observation: MRSA Culture Status | 18 of 22 | 5 of 19 | 41 | NCT01349192 | Trial comparisons |
| Inhaled Vancomycin and Oral Antibiotics vs Inhaled Placebo (Sterile Water) and Oral Antibiotics: deaths from any cause | 0 of 14 | 0 of 15 | 29 | NCT01594827 | Trial comparisons |
| Inhaled Vancomycin and Oral Antibiotics vs Inhaled Placebo (Sterile Water) and Oral Antibiotics: serious adverse events | 1 of 14 | 3 of 15 | 29 | NCT01594827 | Trial comparisons |
| Inhaled Vancomycin and Oral Antibiotics vs Inhaled Placebo (Sterile Water) and Oral Antibiotics: Percentage of Patients MRSA Free by Induced Sputum Respiratory Tract Culture | 5 of 10 | 6 of 15 | 25 | NCT01594827 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100073/comparisons